20 results
Keyword Aybintio Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Aybintio
bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 19/08/2020,,
, Revision: 4, Authorised, Last updated: 10/09/2021
Aybintio Digestive System Diseases Digestive … Aybintio … RISK MANAGEMENT PLAN FOR AYBINTIO This is a summary of the … -
List item
Human medicine European public assessment report (EPAR): Onbevzi
bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 11/01/2021,,
, Revision: 1, Authorised, Last updated: 10/09/2021
cell lung cancer showed that Aybintio was as effective as Avastin … treatment in 50% of those given Aybintio and 45% of those given Avastin … lung cancer showed that Aybintio was as effective as Avastin … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2020
CHMP, Last updated: 26/06/2020Aybintio … -
List item
List of medicines under additional monitoring
Last updated: 25/05/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 17-20 May 2021
European Medicines Agency, Amsterdam, the Netherlands, from 17/05/2021 to 20/05/2021, Last updated: 07/12/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 22-25 March 2021
European Medicines Agency, Amsterdam, the Netherlands, from 22/03/2021 to 25/03/2021, Last updated: 07/12/2021 -
List item
Download medicine data
Last updated: 02/12/2021 -
List item
CHMP: Agendas, minutes and highlights (updated)
Last updated: 17/06/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 3-6 May 2021
European Medicines Agency, Amsterdam, the Netherlands, from 03/05/2021 to 06/05/2021, Last updated: 27/02/2018 -
List item
Committee for Medicinal Products for Human Use (CHMP): 8-11 November 2021
Online, from 08/11/2021 to 11/11/2021, Last updated: 20/01/2022 -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 22/06/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 27-30 September 2021
European Medicines Agency, Amsterdam, the Netherlands, from 27/09/2021 to 30/09/2021, Last updated: 27/02/2018 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 3-6 May 2021
PRAC, Last updated: 07/05/2021 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27-30 September 2021
PRAC, Last updated: 01/10/2021 -
List item
News: Human medicines: highlights of 2020
Last updated: 21/01/2021Tetra MenQuadfi Mvabea Supemtek Vaxchora Zabdeno Cancer Aybintio Ayvakyt Blenrep Cabazitaxel … -
List item
Annual reports and work programmes (updated)
Last updated: 10/06/2022 -
List item
News: Annual report 2020 published
Last updated: 14/06/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 19-22 July 2021
European Medicines Agency, Amsterdam, the Netherlands, from 19/07/2021 to 22/07/2021, Last updated: 07/10/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 13-16 September 2021
European Medicines Agency, Amsterdam, the Netherlands, from 13/09/2021 to 16/09/2021, Last updated: 04/11/2019 -
List item
Public data from Article 57 database
Last updated: 02/06/2021